Publication of NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen halted disease progression and continuously improved quality of life at 35-, 66- and 85-week analyses Data demonstrates consistent and sustained benefit on
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease
Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by Ionis Ionis to receive a $60 million upfront payment CARLSBAD, Calif. , Sept. 27, 2023 /PRNewswire/ — Ionis Pharmaceuticals , Inc.
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent Olezarsen demonstrated a favorable
Ionis to host investor and analyst day event
Ionis Innovation Day: Discovering, Developing and Delivering Transformational Medicines Presentations by key members of Ionis leadership and notable KOLs CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host an investor and
Ionis reports second quarter 2023 financial results
Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks; December 22, 2023 PDUFA date Completed enrollment in donidalorsen OASIS-HAE study and eplontersen CARDIO-TTRansform ATTR-CM study keeping Phase 3 data readouts on track On track to achieve 2023